« Return to News | Drug Sponsors

Lundbeck, CHDI Foundation collaborate on Huntington’s disease

Tuesday, May 22, 2012 10:23 AM

Lundbeck, a pharmaceutical company based in Deerfield, Ill. and CHDI Foundation, a not-for-profit biomedical research organization, have formed a research collaboration to investigate a targeted therapy for Huntington’s disease.

As part of the collaboration CHDI will conduct pre-clinical studies on a Lundbeck investigative compound. Research will focus on the compound’s effect on P2X receptors that may be involved in Huntington’s. The study results will influence future research into this and other compounds for Huntington’s.

“One of our important functions at CHDI is to seek out promising research ideas in the HD field, and this includes this interesting new work on Lundbeck’s compound,” noted Ignacio Munoz-Sanjuan, vice president of translational biology, CHDI. “Lundbeck has a proven track record of not only bringing new therapies to market but also working to support the needs of their patient communities. We hope this research collaboration provides a stepping stone for future therapies that slow the progression of HD.”

Currently, no treatment exists to slow or halt the progression of Huntington’s disease, a challenging hereditary neurodegenerative disease characterized by a triad of behavioral, cognitive and motor symptoms.

Staffan Schüberg, president of Lundbeck, added, “We are also pleased that this announcement coincides with HD Awareness Month, to help draw attention to the need to find therapies for this degenerative neurological disease.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.